MRK
Merck & Co Inc
NEW YORK STOCK EXCHANGE, INC.· Pharmaceuticals· US· IPO 1941-01-01
$151.64
+1.78 (+1.19%)
last quote
Want the full multi-source brief on MRK?
The agent pulls regulatory filings, news flow, prediction-market pricing, and macro context — then synthesizes what's not yet in the price.
Today
Open
$151.64
High
$152.69
Low
$149.97
Previous close
$149.86
Fundamentals
Market cap
$329.55B
P/E (TTM)
103.86x
P/S (TTM)
4.95x
P/B
4.97x
Gross margin
77.28%
Operating margin
9.58%
Net margin
4.77%
Rev growth (YoY)
4.64%
EPS growth (YoY)
-80.70%
ROE
17.93%
52W high
$156.92
52W low
$77.58
Beta
0.14x
Industry peers
by market cap
Upcoming earnings
next 30 days
2026-10-29in 55 days
Q3 2026EPS est $2.24Rev est $17503.1M
Recent SEC filings
CIK 310158filing-language history →
Recent news
2026-08-27 → 2026-09-03
Yahoo · 10h
Amgen Stock Signals Its Confidence. The Market Agrees.
The real bet is on what lies beyond this year's performance: a pipeline that could change everything.
Yahoo · 12h
How Did Merck Stock Beat The Market With Slowing Sales?
Before the eighty-five percent surge, the company's pipeline story was getting louder just as its revenue trajectory was getting quieter.
Yahoo · 13h
Beyond The Cloud Giants: What Could Power NVIDIA Stock From Here?
The market is obsessed with a handful of hyperscalers, but the real story might be the thousands of customers you've never heard of.
Yahoo · 15h
AZN Stock Down 20% in 6 Months: How to Play After Pipeline Setbacks
AstraZeneca's pipeline setbacks weigh on the stock, but blockbuster drugs, oncology growth and a strong launch pipeline offer reasons to stay invested.
Yahoo · 15h
Can LLY's Merida Deal Boost Its M&A Push to Diversify Beyond GLP-1s?
Eli Lilly's 10th deal of 2026 expands its immunology pipeline, underscoring an aggressive push to build growth drivers beyond its blockbuster cardiometabolic franchise.
Yahoo · 17h
Global Health Leader Jeffrey L. Sturchio, PhD, Joins FINN Partners' Health Policy and Impact Group as Senior Advisor
FINN Partners, one of the world's largest independent communication, public affairs and marketing firms, today announced that Jeffrey L. Sturchio, PhD, is joining as a senior adviser. He will be part of FINN's Global Health Practice and work with the Health Policy and Impact Group. Dr. Sturchio's appointment strengthens a multinational team whose expertise spans health policy, stakeholder engageme
Yahoo · 19h
Merck to Participate in the Wells Fargo 21st Annual Healthcare Conference
RAHWAY, N.J., September 02, 2026--Merck to Participate in the Wells Fargo 21st Annual Healthcare Conference
Yahoo · 1d
Did Merck’s (MRK) First Positive Phase 3 Individualized mRNA Cancer Trial Just Redefine Its Moat?
In August 2026, Merck & Co., Inc. and Moderna, Inc. reported that their Phase 3 INTerpath-001 trial of individualized mRNA therapy intismeran autogene plus KEYTRUDA in completely resected stage IIB–IV melanoma met its primary and key secondary endpoints, improving recurrence-free and distant metastasis-free survival versus KEYTRUDA alone with no new safety issues identified. This marks the first p
This is the free preview
The agent layer adds regulatory-language drift detection, cross-venue prediction-market signals, macro overlays, programmable alert rules, overnight briefs, and a grounding verifier on every claim. 7-day Pro trial, no card required.
Start the trial